#USA #Richmond #Indivior #opioid use disorder #Buprenorphine

Indivior Showcases Real-World Evidence at AMCP Nexus 2025

In a significant presentation at the Academy of Managed Care Pharmacy (AMCP) Nexus 2025 conference, Indivior PLC unveiled three new studies exploring the clinical and economic benefits linked to the monthly injectable form of buprenorphine, known as SUBLOCADE. These findings emphasize the importance of adherence to this treatment option for individuals battling opioid use disorder (OUD). The research indicates that patients with higher adherence rates witnessed a marked decrease in both healthcare resource usage and relapse incidents.

Insights from the Presentation

During the conference, Christian Heidbreder, Ph.D., Chief Scientific Officer at Indivior, commented on the essence of these findings, stating, "These new findings reinforce what key stakeholders have long sought: treatment that delivers both better outcomes for patients and greater value for the health system." He emphasized that when patients actively engage with their treatment plans, the injectable medication can significantly reduce the reliance on emergency services, inpatient care, and detox visits, ultimately benefiting patients and the healthcare system alike.

Study Highlights:

1. Medicaid Patients and Healthcare Utilization
A retrospective analysis revealed that Medicaid patients who adhered closely to the SUBLOCADE regimen had substantially lower healthcare utilization than their low-adherence counterparts. Key findings included:
- Emergency Department Visits: Reducation to 48.3% from 65.9% for any causes and to 3.8% from 12.9% for OUD-related reasons.
- Inpatient Admissions: Reduced rates from 7.7% to 18.2% overall and from 0.1% to 0.5% for OUD-related admissions.
- Detox visits showed a similar decline, from 9.3% to 28.4%.
- A notable drop was observed in the recurrence of OUD symptoms, decreasing from 27.6% to 7.6%.

2. Commercially Insured OUD Patients
Another parallel analysis focused on patients with commercial insurance, reinforcing the previous outcomes. Key insights included:
- Emergency room visits were reduced significantly from 24.2% to 38.9%.
- Detox visits halved from 9.6% to 20.4%, indicating effective management strategies for OUD.
- A significant reduction in total medical costs was reported, with average totals dropping from $43,357 to $23,051, thus providing compelling evidence of the treatment's economically beneficial position.

3. Impact on Infectious Disease Management
A retrospective cohort study investigated the impact of SUBLOCADE on managing infectious diseases among patients with OUD. Results indicated a substantial reduction in the incidence of:
- Acute skin infections (37% lower) and bacteremia (62% lower).
- Outpatient visits related to sexually transmitted infections also saw a reduction of 77%. This implies that regular clinical follow-ups associated with SUBLOCADE treatment may enhance the management of chronic health issues.

Noteworthy Considerations

While these findings are promising, the study also acknowledged certain limitations. The retrospective nature of the analysis might have introduced biases, particularly since it included periods during the COVID-19 pandemic, which influenced healthcare access.

About SUBLOCADE

SUBLOCADE, an extended-release buprenorphine injection, is designed for the treatment of moderate to severe opioid use disorder and is recommended to be part of a comprehensive plan including counseling and psychosocial support.

Safety Information

It is critical to note that SUBLOCADE has serious risks associated with intravenous use, including the potential for serious harm or death. Healthcare providers must adhere to the stringent requirements of the SUBLOCADE REMS Program to mitigate these risks.

Conclusion

Indivior is committed to facilitating transformative change in the treatment landscape of opioid use disorder. With a robust pipeline of treatments, the aim is to ensure that patients can access effective, evidence-based care. For more information about SUBLOCADE and other treatment options, visit Indivior’s official website.